Orbis Diagnostics welcomes Dr Vijay Aggarwal and Sarah Park to its board of directors and appoints Dr Maher Khaled to the executive team as the company's Director – Business Development.
Orbis CEO, Damian Camp said “These new appointments underpin an exciting stage in our development which comes off the back of proving our platform technology through the development of the COVID-19 immunity test.
“This is a transformative time for Orbis. We are well into the development of our next group of diagnostics tests which will support a future where high-quality medical testing is accessible to all by enabling the continued growth of the telehealth sector.
“As we shift through this next stage of growth with the aim of commercialising our platform technology, the skills, diverse views, and wealth of experience which Dr Aggarwal and Ms Park bring to the Board will be highly complementary to the expertise of our current board members and will be instrumental to achieving success.
“Based in the United States, Dr Vijay Aggarwal joins the Orbis board as Chairman. Dr Aggarwal brings extensive leadership in clinical diagnostic services as well as institutional and individual investment experience. He has led several pharmaceutical and biotech ventures through successive phases of high growth, including as the former President of Quest Diagnostic Ventures.
“Sarah Park has a strong international executive pedigree in corporate finance and capital markets. Alongside her role with Orbis Diagnostics, she holds a number of Independent Directorship roles including Director and Chair of the Audit &Risk Committee of the NZX/ASX listed Pacific Edge, a global cancer diagnostics company. Sarah also co-founded Even Capital, a major shareholder in Orbis Diagnostics, to focus on funding female-founded growth stage businesses in Asia Pacific.
“In addition to the new board members, I am delighted to have Dr Maher Khaled join Orbis’ executive team as Director – Business Development. Maher is tasked with driving strategic partnerships and alliances for the company.
“With a PhD in biotechnology and Bachelor of Laws from the University of Queensland, Maher has 17 years’ experience in commercialising biotechnology, working for the likes of McKinsey & Co in London, Cambridge Enterprise Ltd in Cambridge UK, and most recently as Director – Business Development for ASX listed, digital diagnostic company ResApp Health in Brisbane, Australia.
“Our focus remains firmly on addressing unmet global health needs. While our R&D will continue to work on detecting immunity to Covid-19 and other infectious diseases, we have recognised the valuable opportunity for our platform technology to overcome significant international health challenges. For example sexually transmitted infections and liver damage as a result of hepatitis infection and substance abuse, are two meaningful global issues where the inability to access reliable, accurate and quick diagnosis is having a major negative impact.
“The future is exciting. The entire team is committed to executing on these partnerships and working closely to develop new applications to drive the company towards achieving commercial success,” said Mr Camp.